BioStem Technologies has appointed Jodi Ungrodt to its board of directors, with responsibility for chairing the audit committee. The appointment comes as the medtech company expands beyond chronic wound care and prepares for further public markets activity in 2026.
Board appointment adds financial and regulatory experience
Ungrodt joined the board with effect from 18 March. BioStem said she brings nearly 29 years of accounting and advisory experience in the life sciences sector.
During her career at Ernst & Young, she advised companies on public offerings, business combinations, risk assessment and regulatory compliance. The company said she qualifies as a financial expert under SEC, NYSE and Nasdaq rules.
Audit committee role supports governance plans
As audit committee chair, Ungrodt will oversee financial reporting, internal controls and risk management. BioStem said the appointment supports its governance structure as the business broadens its commercial focus.
The company develops, manufactures and commercialises placental-derived and umbilical cord-derived products for advanced wound care and other clinical applications.
BioStem outlines next phase of growth
BioStem said it is expanding beyond chronic wound care while also seeking to raise its public market profile this year. The company added that its product portfolio is used across multiple medical specialties and is supported by ongoing research into placental-derived tissue products.
Ungrodt holds a BS in Accounting from San Diego State University and is a Certified Public Accountant. She is also an advisory board member of Life Science Cares.
Leadership transition follows previous board change
Ungrodt replaces Brandon Poe on the board. Poe accepted the role of chief financial officer in August 2025 after serving on BioStem’s board for three years.
Further information is available on the BioStem Technologies website. Related coverage can be found in the People & Leadership section.
